Industry top-down
Drug Manufacturers - General
Latest reported revenue & EPS across the covered companies in this industry, with year-over-year (YoY) change. From disclosed earnings — not investment advice.
AI industry top-down
Overall, sales growth trends across the pharmaceutical industry were mixed. While some companies recorded robust sales growth, many faced sales declines or stagnation. EPS, a key profitability metric, also showed varying trends across companies. Some companies saw EPS decline despite increased sales, while others managed to grow EPS even with a slight decrease in sales. This suggests significant disparities in company performance within the industry.
- Mixed revenue growth across companies
- Divergent trends in profitability metrics (EPS)
AI synthesis of disclosed results and analyst research across these companies — not investment advice.
Companies — latest quarter
| Company | Period | Revenue | Rev YoY | EPS | EPS YoY | Surprise |
|---|---|---|---|---|---|---|
| LLYELI LILLY & Co | FY2026 Q3 | $24.4B | +38.6% | $7.22 | +16.3% | — |
| JNJJOHNSON & JOHNSON | FY2026 Q3 | $25.4B | +5.9% | $0.09 | -95.8% | — |
| ABBVAbbVie Inc. | FY2026 Q3 | $17.4B | +10.3% | $2.37 | — | — |
| MRKMerck & Co., Inc. | FY2026 Q3 | $18.09B | +4.7% | $2.04 | -12.1% | — |
| AMGNAMGEN INC | FY2026 Q3 | $10.37B | +8.5% | $7.08 | +19.4% | — |
| GILDGILEAD SCIENCES, INC. | FY2026 Q3 | $8.3B | +6.8% | $1.94 | -20.2% | — |
| PFEPFIZER INC | FY2026 Q3 | $16.58B | -0.4% | $0.56 | -9.7% | — |
| BMYBRISTOL MYERS SQUIBB CO | FY2026 Q3 | $13.07B | +6.9% | $1.05 | -2.8% | — |
| BIIBBIOGEN INC. | FY2026 Q3 | $2.8B | +10.6% | $-0.14 | — | — |
| OGNOrganon & Co. | FY2026 Q3 | $1.57B | -1.7% | $0.60 | -1.6% | — |
| AMRNAMARIN CORP PLCUK | FY2026 Q3 | $39.55M | -20.4% | $0.00 | — | — |
| 317450MYUNGIN PHARM.CO., LTD | FY2026 Q2 | ₩76.11B | — | ₩1666.00 | — | — |
| 307750KUKJEON Co.,Ltd | FY2026 Q2 | ₩40.48B | +21.4% | ₩19.00 | — | — |
| 004720PharmGen Science, Inc. | FY2026 Q2 | ₩47.72B | +4.0% | ₩-614.00 | — | — |
YoY = vs. the same quarter last year · Surprise = EPS actual vs. consensus. Latest reported quarter per company, from disclosed earnings filings. QoQ is omitted because quarterly filings don’t break out Q4 (US) and report cumulatively (KR).